Skip to main content
SpringerLink
Log in

Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”

  • Letter to the Editor
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Frapaise F-X. The end of phase 3 clinical trials in biosimilars development? BioDrugs. 2018;32(4):319–24. https://doi.org/10.1007/s40259-018-0287-0.

    Article  CAS  PubMed  Google Scholar 

  2. Webster CJ, Woollett GR. Comment on “the end of phase 3 clinical trials in biosimilars development?”. BioDrugs. 2018;32(5):519–21.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Niazi S. Obstacles to success for biosimilars in the US market. Posted 4 January 2018. https://www.europeanpharmaceuticalreview.com/article/70987/obstacles-success-biosimilars-us-market/. Accessed 20 Dec 2018.

  4. Niazi S. Rationalizing FDA guidance on biosimilars—expediting approvals and acceptance. 23 July 2018. http://gabi-journal.net/rationalizing-fda-guidance-on-biosimilars-expediting-approvals-and-acceptance.html. Accessed 20 Dec 2018.

  5. Niazi, S. e-Book Challenges Facing Biosimilars Entries into US Markets. https://bioprocessintl.com/manufacturing/biosimilars/ebook-challenges-facing-biosimilar-products-us-markets/. Accessed 20 Dec 2018.

  6. FDA: Citizen Petition by Sarfaraz Niazi and additional postings by the FDA. https://www.regulations.gov/docket?D=FDA-2018-P-1876. Accessed 20 Dec 2018.

  7. FDA: Withdrawn Guidance: Statistical Approaches to Evaluate Analytical Similarity Guidance for Industry. https://www.pbwt.com/content/uploads/2018/06/UCM576786.pdf. Accessed 20 Dec 2018.

  8. Scientist Invented A New Pathway To Approve Biosimilars, And The FDA Is Listening. Forbes Magazine 25 July 2018; https://www.forbes.com/sites/nicolefisher/2018/07/25/one-mans-mission-to-fix-the-fdas-biosimilar-problem/#56122f9d2380. Accessed 20 Dec 2018.

  9. FDA: Biosimilars Action Plan (BAP) issued 1 July 2018; https://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM613761.pdf. Accessed 20 Dec 2018.

  10. Amgen Biosimilars. Clinical data. https://www.amgenbiosimilars.com/expertise/clinical-testing/. Accessed 20 Dec 2018.

  11. ICH E6 guideline for good clinical practice: a trial should be initiated and continued only if the anticipated benefits justify the risks. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed 20 Dec 2018.

  12. US: Public Law 98-417. https://www.gpo.gov/fdsys/pkg/STATUTE-98/pdf/STATUTE-98-Pg1585.pdf. Accessed 20 Dec 2018.

  13. The Biologics Price Competition and Innovation Act of 2009, (BPCIA), 42 USC 262(k). https://www.fda.gov/downloads/drugs/ucm216146.pdf. Accessed 20 Dec 2018.

  14. FDA: Biosimilar Approval Pathway; https://www.fda.gov/downloads/AboutFDA/WorkingatFDA/FellowshipInternshipGraduateFacultyPrograms/PharmacyStudentExperientialProgramCDER/UCM587522.pdf. Accessed 20 Dec 2018.

  15. US Title 21CFR320.22, Criteria for waiver of evidence of in vivo bioavailability or bioequivalence. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=320.22. Accessed 20 Dec 2018.

  16. Niazi S. Volume of distribution as a function of time. J Pharm Sci. 1976;65(3):452–4.

    Article  CAS  PubMed  Google Scholar 

  17. Pineda C, Hernández GC, Jacobs IA, Alvarez DF, Carini C. Assessing the immunogenicity of biopharmaceuticals. BioDrugs. 2016;30(3):195–206. https://doi.org/10.1007/s40259-016-0174-5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. FDA: Approved Biosimilars; https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/ucm580432.htm. Accessed 20 Dec 2018.

  19. FDA’s Leah Christl Provides an Agency Perspective on the Biosimilars Landscape. https://www.centerforbiosimilars.com/conferences/alliance-for-patient-access-2018/fdas-leah-christl-provides-an-agency-perspective-on-the-biosimilars-landscape. Accessed 20 Dec 2018.

  20. Dunn, A. FDA’s Woodcock: ‘The clinical trial system is broken’ https://www.biopharmadive.com/news/fdas-woodcock-the-clinical-trial-system-is-broken/542698/. Accessed 20 Dec 2018.

  21. Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017;377:62–70. https://doi.org/10.1056/NEJMra1510062.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of Illinois, Chicago, IL, USA

    Sarfaraz K. Niazi

Authors
  1. Sarfaraz K. Niazi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sarfaraz K. Niazi.

Ethics declarations

Funding

No funding was received.

Conflict of interest

Sarfaraz K. Niazi has no conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Niazi, S.K. Comment on “The End of Phase 3 Clinical Trials in Biosimilars Development?”. BioDrugs 33, 121–123 (2019). https://doi.org/10.1007/s40259-018-0330-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40259-018-0330-1

Search

Navigation